RPT1G for Acute Myeloid Leukemia and Myelodysplastic Syndrome

This trial tests a new treatment called RPT1G for certain blood cancers: acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The main goal is to determine RPT1G's safety and identify the optimal dose and schedule. The trial includes four groups, each receiving a different dose to assess effectiveness. Suitable participants have relapsed or hard-to-treat AML or high-risk MDS and have either tried standard treatments or opted not to. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this new treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

A previous study showed that RPT1G is a safe treatment. In trials with 56 healthy volunteers, 42 received RPT1G and experienced no severe side effects. Most side effects were mild to moderate, indicating they were not serious. RPT1G is well-tolerated and works by blocking a specific enzyme. It has been tested at various dose levels without major safety concerns. These early results are encouraging for its potential use in treating conditions like acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).¹²³⁴⁵

RPT1G is unique because it offers a novel approach to treating Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) by targeting the cancer cells more precisely. Unlike the standard treatments, which often include chemotherapy drugs like cytarabine and daunorubicin, RPT1G aims to disrupt specific pathways that are crucial for cancer cell survival. Researchers are excited about RPT1G because it has the potential to be more effective with fewer side effects, making it a promising option for patients who have limited treatment choices.

Research has shown that RPT1G is a promising treatment for acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). RPT1G is the first treatment of its kind that is well-tolerated, targeting a specific protein that aids cancer cell survival. In earlier studies, 11% of patients experienced a complete response, with effects lasting about 24 months on average. Patients had a median time of 9.5 months before disease progression and lived for an average of 18.8 months overall. This trial will evaluate different dosing levels of RPT1G across various cohorts to determine its effectiveness and safety. These results suggest that RPT1G could be an effective option for treating these challenging blood cancers.²⁴⁶⁷⁸